Margaret Olinger

Margaret Olinger is a declared insider of Amylyx Pharmaceuticals, Inc. (senior executive), with filings sourced from SEC (Form 4). We count 8 filings; the first trade dates from 6 January 2022 and the latest from 27 December 2023.

In open-market terms, that means 1 purchase worth €115k on one side and 2 sales worth €83k on the other. The net balance comes to €32k on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants and 2 option exercises. So far in 2023, the count stands at no purchases and 2 sales.

On 29 December 2023 came the latest disclosure, an option exercise for €8,376 in Amylyx Pharmaceuticals, Inc. The last insider purchase was made public on 10 January 2022, 1,764 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.